Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study.

doi:10.1016/j.ebiom.2020.102643

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study.

EBioMedicine - 1 Mar 2020

Hosen Md Ismail, Sheikh Mahdi, Zvereva Maria, Scelo Ghislaine, Forey Nathalie, Durand Geoffroy, Voegele Catherine, Poustchi Hossein, Khoshnia Masoud, Roshandel Gholamreza, Sotoudeh Masoud, Nikmanesh Arash, Etemadi Arash, Avogbe Patrice Hodonou, Chopard Priscilia, Delhomme Tiffany Myriam, Foll Matthieu, Manel Arnaud, Vian Emmanuel, Weiderpass Elisabete, Kamangar Farin, Boffetta Paolo, Pharaoh Paul D, Dawsey Sanford M, Abnet Christian C, Brennan Paul, McKay James, Malekzadeh Reza, Calvez-Kelm Florence Le

Abstract excerpt

BACKGROUND: Detecting pre-clinical bladder cancer (BC) using urinary biomarkers may provide a valuable opportunity for screening and management. Telomerase reverse transcriptase (TERT) promoter mutations detectable in urine have emerged as promising BC biomarkers. METHODS: We performed a nested case-control study within the population-based prospective Golestan Cohort Study (50,045 participants, followed up to 14...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Cohort Studies

Share to Early Diagnosis

Share to Genetic Testing

Share to Promoter Regions, Genetic

Share to Telomerase

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32081602
DOI: 10.1016/j.ebiom.2020.102643
PMCID: PMC7118568

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study.PMID 32081602Read ↗

TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region.Semantic proximity Read ↗

Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer.Semantic proximity Read ↗

Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.Semantic proximity Read ↗

Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.Semantic proximity Read ↗

Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancerSemantic proximity Read ↗

hTERT, hTR and TERT promoter mutations as markers for urological cancers detection: A systematic review.Semantic proximity Read ↗

Comprehensive Mutation Analysis of the TERT Promoter in Bladder Cancer and Detection of Mutations in Voided UrineSemantic proximity Read ↗

The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer.Semantic proximity Read ↗

High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder.Semantic proximity Read ↗

Novel method for detecting frequent TERT promoter hot spot mutations in bladder cancer samples.Semantic proximity Read ↗

Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.Semantic proximity Read ↗

Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.